netFormulary
 Report : A-Z NHS England items in Formulary 30/03/2020 19:44:37
[Back]
 
Section Status NHS England Name
08.01.05 Formulary MHS England Afatinib Giotrif®
08.01.05 Formulary MHS England Alectinib Alecensa®
08.02.03 Formulary MHS England Alemtuzumab Lemtrada®
08.01.05 Formulary MHS England Arsenic Trioxide Trisenox®
08.02.03 Formulary MHS England Atezolizumab Tecentriq®
08.01.05 Formulary MHS England Avelumab Bavencio®
08.02.04 Formulary MHS England Axicabtagene ciloleucel  Yescarta®
03.04.02 Formulary MHS England Benralizumab Fasenra®
08.02 Formulary MHS England Blinatumomab Blincyto®
08.01.05 Formulary MHS England Brentuximab vedotin Adcetris®
08.01.05 Formulary MHS England Brigatinib Alunbrig®
10.01.03 Formulary MHS England Burosumab Crysvita®
08.01.05 Formulary MHS England Cabozantinib Cabometyx®
08.01.05 Formulary MHS England Cabozantinib Cometriq®
02.09 Formulary MHS England Cangrelor Kengrexal®
08.02.03 Formulary MHS England Cemiplimab Libtayo®
08.01.05 Formulary MHS England Ceritinib Zykadia®
16.01 Formulary MHS England Cerliponase alpha Brineura®
08.01.05 Formulary MHS England Dabrafenib Tafinlar®
08.02.04 Formulary MHS England Daclizumab Zinbryta®
08.01.05 Formulary MHS England Daratumumab Darzalex®
16.01 Formulary MHS England Dibotermin alfa InductOs®
08.02.04 Formulary MHS England Dimethyl fumarate Tecfidera®
08.02.04 Formulary MHS England Dinutuximab Beta Qarziba®
08.01 Formulary MHS England Durvalumab Imfinzi®
08.02.04 Formulary MHS England Fingolimod 
08.02.03 Formulary MHS England Gemtuzumab oxogamicin  Mylotarg®
08.02.04 Formulary MHS England Glatiramer Acetate Copaxone®
05.03.03.02 Formulary MHS England Glecaprevir and Pibrentasvir Maviret®
08.01.05 Formulary MHS England Ibrutinib Imbruvica®
09.08.01 Formulary MHS England Inotersen Tegsedi®
08.01.05 Formulary MHS England Inotuzumab ozogamicin Besponsa®
08.02.04 Formulary MHS England Interferon Beta-1a Avonex®
08.02.04 Formulary MHS England Interferon Beta-1a Rebif®
08.02.04 Formulary MHS England Interferon Beta-1b Extavia®
08.02.04 Non Formulary MHS England Interferon Beta-1b Betaferon®
08.01.05 Formulary MHS England Ixazomib Ninlaro®
16.01 Formulary MHS England Lanadelumab Takhzyro®
08.03.04.03 Formulary MHS England Lanreotide  Somatuline Autogel®
08.02.04 Formulary MHS England Lenalidomide Revlimid®
08.01.05 Formulary MHS England Lenvatinib Lenvima®
08.01.05 Formulary MHS England Lenvatinib Kisplyx®
05.03.02.02 Formulary MHS England Letermovir Prevymis®
05.01.12 Formulary MHS England Levofloxacin Quinsair®
08.01.02 Formulary MHS England Liposomal cytarabine–daunorubicin Vyxeos®
08.03.04.03 Formulary MHS England Lutetium (177Lu) oxodotreotide Lutathera®
02.05.01 Formulary MHS England Macitentan Opsumit®
03.04.02 Formulary MHS England Mepolizumab Nucala®
08.01.05 Formulary MHS England Midostaurin Rydapt®
08.03.04.01 Formulary MHS England Neratinib Nerlynx®
03.11 Formulary MHS England Nintedanib Ofev®
08.01.05 Formulary MHS England Niraparib Zejula®
08.02.04 Formulary MHS England Nivolumab Opdivo®
10.02 Formulary MHS England Nusinersen Spinraza®
08.02.03 Formulary MHS England Obinutuzumab Gazyvaro®
08.03.04.03 Formulary MHS England Octreotide Sandostatin LAR®
08.02.03 Formulary MHS England Ofatumumab Arzerra®
08.02.04 Formulary MHS England Olaparib Lynparza®
09.08.01 Formulary MHS England Patisiran Onpattro®
08.01.05 Formulary MHS England Pazopanib Votrient®
08.01.05 Formulary MHS England Pembrolizumab Keytruda®
08.01.05 Formulary MHS England Pertuzumab Perjeta®
03.11 Formulary MHS England Pirfenidone Esbriet®
08.02.04 Formulary MHS England Pomalidomide Imnovid®
08.01.05 Formulary MHS England Regorafenib Stivarga®
03.04.02 Formulary MHS England Reslizumab Cinquil®
08.02.03 Formulary MHS England Rituximab MabThera®
08.02.04 Formulary MHS England Rucaparib Rubraca®
05.03.03.02 Formulary MHS England Sofosbuvir - Velpatasvir - Voxilaprevir Vosevi®
08.01.05 Formulary MHS England Sorafenib Nexavar®
16.01 Formulary MHS England Strimvelis 
08.01.05 Formulary MHS England Tivozanib Fotivda®
08.01.05 Formulary MHS England Vemurafenib Zelboraf®
16.01 Formulary MHS England Voretigene Neparvovec  Luxturna®
Oxfordshire Clinical Commissioning Group